CPI 1714

Drug Profile

CPI 1714

Alternative Names: NRT 115

Latest Information Update: 14 Jun 2004

Price : $50

At a glance

  • Originator Renovis
  • Class Antirheumatics
  • Mechanism of Action Free radical scavengers; Mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 14 Jun 2004 Discontinued - Preclinical for Rheumatoid arthritis in USA (PO)
  • 16 Dec 2002 Centaur Pharmaceuticals has been acquired by Renovis
  • 19 Dec 2000 CPI 1714 is available for licensing (http://www.centpharm.com/)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top